186 related articles for article (PubMed ID: 38649957)
41. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
42. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
[TBL] [Abstract][Full Text] [Related]
43. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
[TBL] [Abstract][Full Text] [Related]
44. DCZ5248, a novel dual inhibitor of Hsp90 and autophagy, exerts antitumor activity against colon cancer.
Chen XL; Liu P; Zhu WL; Lou LG
Acta Pharmacol Sin; 2021 Jan; 42(1):132-141. PubMed ID: 32404982
[TBL] [Abstract][Full Text] [Related]
45. Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon.
Wu P; Zhou Q; Zhu H; Zhuang Y; Bao J
BMC Cancer; 2020 Apr; 20(1):354. PubMed ID: 32345258
[TBL] [Abstract][Full Text] [Related]
46. Small-molecule dual inhibitors targeting heat shock protein 90 for cancer targeted therapy.
Xie X; Zhang N; Li X; Huang H; Peng C; Huang W; Foster LJ; He G; Han B
Bioorg Chem; 2023 Oct; 139():106721. PubMed ID: 37467620
[TBL] [Abstract][Full Text] [Related]
47. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer.
Bai F; Wang C; Lu Q; Zhao M; Ban FQ; Yu DH; Guan YY; Luan X; Liu YR; Chen HZ; Fang C
Biomaterials; 2013 Aug; 34(26):6163-74. PubMed ID: 23706689
[TBL] [Abstract][Full Text] [Related]
48. CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.
Xu XL; Bao QC; Jia JM; Liu F; Guo XK; Zhang MY; Wei JL; Lu MC; Xu LL; Zhang XJ; You QD; Sun HP
Sci Rep; 2016 Jan; 6():19004. PubMed ID: 26743233
[TBL] [Abstract][Full Text] [Related]
49. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
[TBL] [Abstract][Full Text] [Related]
50. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
51. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
[TBL] [Abstract][Full Text] [Related]
52. Anti-tumor selectivity of a novel tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models.
Zhang Q; Zhai S; Li L; Li X; Zhou H; Liu A; Su G; Mu Q; Du Y; Yan B
Biochem Pharmacol; 2013 Aug; 86(3):351-60. PubMed ID: 23743233
[TBL] [Abstract][Full Text] [Related]
53. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
54.
Tong J; Tan S; Nikolovska-Coleska Z; Yu J; Zou F; Zhang L
Mol Cancer Ther; 2017 Sep; 16(9):1979-1988. PubMed ID: 28619760
[TBL] [Abstract][Full Text] [Related]
55. Targeting CD44 receptor-positive lung tumors using polysaccharide-based nanocarriers: Influence of nanoparticle size and administration route.
Jeannot V; Mazzaferro S; Lavaud J; Vanwonterghem L; Henry M; Arboléas M; Vollaire J; Josserand V; Coll JL; Lecommandoux S; Schatz C; Hurbin A
Nanomedicine; 2016 May; 12(4):921-932. PubMed ID: 26724540
[TBL] [Abstract][Full Text] [Related]
56. Multi-layered cellulose nanocrystal system for CD44 receptor-positive tumor-targeted anticancer drug delivery.
Seo JH; Lee SY; Hwang C; Yang M; Lee J; Lee SH; Cho HJ
Int J Biol Macromol; 2020 Nov; 162():798-809. PubMed ID: 32585268
[TBL] [Abstract][Full Text] [Related]
57. PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy.
Gu G; Hu Q; Feng X; Gao X; Menglin J; Kang T; Jiang D; Song Q; Chen H; Chen J
Biomaterials; 2014 Sep; 35(28):8215-26. PubMed ID: 24974009
[TBL] [Abstract][Full Text] [Related]
58. Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014.
Xiao Y; Liu Y
Curr Drug Targets; 2020; 21(3):302-317. PubMed ID: 31465284
[TBL] [Abstract][Full Text] [Related]
59. Simvastatin functions as a heat shock protein 90 inhibitor against triple-negative breast cancer.
Kou X; Jiang X; Liu H; Wang X; Sun F; Han J; Fan J; Feng G; Lin Z; Jiang L; Yang Y
Cancer Sci; 2018 Oct; 109(10):3272-3284. PubMed ID: 30039622
[TBL] [Abstract][Full Text] [Related]
60. Synergetic cytotoxic activity toward breast cancer cells enhanced by the combination of Antp-TPR hybrid peptide targeting Hsp90 and Hsp70-targeted peptide.
Horibe T; Torisawa A; Kohno M; Kawakami K
BMC Cancer; 2014 Aug; 14():615. PubMed ID: 25159299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
